• 1
    Anderson BO,Yip CH,Smith RA, et al. Guideline implementation for breast healthcare in low and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008; 113( 8 suppl): 22212243.
  • 2
    Kaufmann M,von Minckwitz G,Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003; 21: 2600268.
  • 3
    Parkin DM,Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006; 12( suppl 1): S70S80.
  • 4
    Hortobagyi GN,de la Garza Salazar J,Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005; 6: 391401.
  • 5
    Smigal C,Jemal A,Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006; 56: 168183.
  • 6
    Agarwal G,Pradeep PV,Aggarwal V,Yip CH,Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007; 31: 10311040.
  • 7
    El Saghir NS,Khalil MK,Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007; 5: 225233.
  • 8
    Fregene A,Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer. 2005; 103: 15401550.
  • 9
    Rodriguez-Cuevas S,Macias CG,Franceschi D,Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 2001; 91: 863868.
  • 10
    Anderson BO,Shyyan R,Eniu A, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J. 2006; 12( suppl 1): S3S15.
  • 11
    GreeneFL,PageDL,FlemingID, et al, eds. AJCC Cancer Staging Manual,6th ed. New York, NY: Springer-Verlag; 2002.
  • 12
    Singletary SE,Allred C,Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 36293636.
  • 13
    Shyyan R,Sener SF,Anderson BO, et al. Breast health guideline implementation in low- and middle-income countries: diagnosis resource allocation. Cancer. 2008; 113( 8 suppl): 22572268.
  • 14
    Pestalozzi BC,Luporsi-Gely E,Jost LM,Bergh J. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol. 2005; 16( suppl 1): i7i9.
  • 15
    National Comprehensive Cancer Network (NCCN). Breast Cancer. 2008 V2.2 Available at: Accessed on June 10, 2008.
  • 16
    Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer. 2007; 110: 23942407.
  • 17
    Bonadonna G,Valagussa P,Brambilla C, et al. Primary chemotherapy in operable breast cancer: 8-year experience at the Milan Cancer Institute. J Clin Oncol. 1998; 16: 93100.
  • 18
    Fisher B,Bryant J,Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 26722685.
  • 19
    Wolmark N,Wang J,Mamounas E,Bryant J,Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;(30): 96102.
  • 20
    Mauriac L,MacGrogan G,Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999; 10: 4752.
  • 21
    Buzdar AU,Singletary SE,Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999; 17: 34123417.
  • 22
    Smith IC,Heys SD,Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 14561466.
  • 23
    Heys SD,Hutcheon AW,Sarkar TK, et al; Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002; 3( suppl 2): S69S74.
  • 24
    Hurley J,Reis I,Silva O, et al. Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Clin Breast Cancer. 2005; 5: 447454.
  • 25
    Hurley J,Doliny P,Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006; 24: 18311838.
  • 26
    Bear HD,Anderson S,Brown A, et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 41654174.
  • 27
    Bear HD,Anderson S,Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24: 20192027.
  • 28
    Mauri D,Pavlidis N,Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 188194.
  • 29
    Zielinski S. Press release: neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds. J Natl Cancer Inst. 2005; 97: 157.
  • 30
    Davidson NE,Morrow M. An assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst. 2005; 97: 159161.
  • 31
    Rastogi P,Anderson SJ,Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26: 778785.
  • 32
    Albain KS,Green SJ,Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814) [abstract]. Proc ASCO. 2002; 21: 37a.
  • 33
    Thomas E,Holmes FA,Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004; 22: 22942302.
  • 34
    Mazouni C,Kau SW,Frye D, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007; 18: 874880.
  • 35
    Goble S,Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am. 2003; 83: 943971.
  • 36
    Estevez LG,Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004; 10: 32493261.
  • 37
    Heys SD,Sarkar T,Hutcheon AW. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat. 2005; 90: 169185.
  • 38
    Green MC,Buzdar AU,Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 59835992.
  • 39
    von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother. 2007; 8: 485495.
  • 40
    Buzdar AU,Valero V,Ibrahim NK, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 36763685.
  • 41
    Buzdar AU,Valero V,Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13: 228233.
  • 42
    Dawood S,Gonzalez-Angulo AM,Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer. 2007; 110: 11951200.
  • 43
    Burstein HJ,Harris LN,Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003; 21: 4653.
  • 44
    Halyard MY,Pisansky TM,Solin LJ, et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group phase III trial N9831 [abstract]. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2006; 24(18S). Abstract 523.
  • 45
    Mauriac L,Debled M,Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 2002; 13: 293298.
  • 46
    Ellis MJ,Coop A,Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 38083816.
  • 47
    Eiermann W,Paepke S,Appfelstaedt J, et al; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12: 15271532.
  • 48
    Semiglazov VF,Semiglazov VV,Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110: 244254.
  • 49
    Smith IE,Dowsett M,Ebbs SR, et al; IMPACT Trialists' Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double- blind randomized trial. J Clin Oncol. 2005; 23: 51085116.
  • 50
    Cataliotti L,Buzdar AU,Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006; 106: 20952103.
  • 51
    Silva OE,Zurrida S. Neoadjuvant endocrine therapy in LABC. In: SilvaO,ZurridaS, eds. Breast Cancer: A Practical Guide,3rd ed. New York, NY: Elsevier; 2005: 251253.
  • 52
    Chao Clifford KS,Perez CA,Brady LW. Locally advanced breast cancer (T3 and T4), inflammatory and recurrent tumors. In: ChaoKSC,BradyLW, eds. Radiation Oncology Management Decisions,2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1999: 369377.
  • 53
    Sachelarie I,Grossbard ML,Chadha M,Feldman S,Ghesani M,Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006; 11: 574589.
  • 54
    Cataliotti L,De Wolf C,Holland R, et al; EUSOMA. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer. 2007; 43: 660675.
  • 55
    Onyango M. Breast health program in Kenya. Presented at the Breast Health Global Initiative Global Summit, Budapest, Hungary, October 1-4, 2007.
  • 56
    Angell M. Drug Prices and Pharmaceuticals. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House; 2004.
  • 57
    World Health Organization. Essential Medicines. WHO Model List, 2005. Available at: Accessed on June 10, 2008.
  • 58
    US Food and Drug Administration. Drug Patents. FDA website. Available at: Accessed on June 10, 2008.
  • 59
    Milt Freudenheim. As Drug Patents End, Costs for Generics Surge. New York Times. Friday, December 27, 2002.
  • 60
    Joensuu H,Kellokumpu-Lehtinen PL,Bono P, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809820.
  • 61
    National Institutes of Health. Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. National Institutes of Health, October 2007. Available at: Accessed on June 10, 2008.
  • 62
    Wagstaff A. PHARE, shining an academic light on research in Europe. Cancer World. 2006. Available at: Accessed on June 10, 2008.